Arvinas Inc $ARVN

Recent News (3)

• Arvinas to Participate in Upcoming Investor Conferences GlobeNewswire · 03 Sep 2026 NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted…
• Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 01 Sep 2026 NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted…
• Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 GlobeNewswire · 28 Jul 2026 NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that ma…